p-phenylene-bis-methanesulfonyl chloride | 51259-16-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: p-phenylene-bis-methanesulfonyl chloride
• 英文别名: p-Phenylen-bis-methansulfonylchlorid；[4-(Chlorosulfonylmethyl)phenyl]methanesulfonyl chloride
• CAS: 51259-16-6
• 化学式: C₈H₈Cl₂O₄S₂
• 分子量: 303.187
• InChiKey: QXZCQTNPAAKLSZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  85
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  9-氨基-(9-脱氧)表辛可尼丁三盐酸盐 、 p-phenylene-bis-methanesulfonyl chloride 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成
  参考文献：
  名称：

  基于金鸡纳生物碱的手性超支化聚合物的制备及其不对称反应催化活性研究。

  摘要：

  金鸡纳生物碱衍生的磺酰胺和含有手性超支化聚合物的酯二聚体已成功合成并用作不对称反应的催化剂。通过 Mizoroki-Heck 偶联聚合合成了几种源自金鸡纳生物碱并掺入磺酰胺和酯的超支化聚合物。这些聚合物随后应用于对映选择性迈克尔加成反应。由于所制备的聚合物不溶于常用的有机溶剂，因此它们在β-酮酯对硝基烯烃的对映选择性反应中充当有效的催化剂，实现高达99%的对映选择性和良好的产率。不溶性的特性使它们能够更好地满足“绿色化学”的要求，并且可以多次使用而不失去对映选择性。

  DOI：

  10.55730/1300-0527.3677
• 作为产物：
  描述：

  1,4-对二氯苄 在 sodium disulfide 作用下， 生成 p-phenylene-bis-methanesulfonyl chloride
  参考文献：
  名称：

  DE885847

  摘要：

  公开号：

文献信息

• Novel therapeutic agents for membrane transporters
  申请人：——

  公开号：US20030044845A1

  公开（公告）日：2003-03-06

  Novel multi-binding compounds (agents) are disclosed which bind cell membrane transporters including ion channels, molecular transporters and ion pumps. The compounds of this invention comprise from 2 to 10 ligands each of which can bind to such cellular transporters to modulate the biological processes/functions thereof. Each of the ligands is covalently attached to a linker (framework) to provide for a multi-binding compound. The linker is selected such that the multi-binding compound exhibits increased modulation of the biological processes/functions of the transporter as compared to the aggregate of the individual ligand units made available for binding to the transporter.

  本发明揭示了一种新型多重结合化合物（试剂），其结合细胞膜转运体，包括离子通道、分子转运体和离子泵。本发明的化合物包括2到10个配体，每个配体都可以结合到这些细胞转运体上，以调节其生物过程/功能。每个配体都共价地连接到一个连接器（框架）上，以提供多重结合化合物。所选择的连接器是为了使多重结合化合物相比可用于结合转运体的单个配体单元的聚合体表现出增强的调节转运体的生物过程/功能的特性。
• NOVEL POTASSIUM CHANNEL DRUGS AND THEIR USES
  申请人：Advanced Medicine, Inc.

  公开号：EP1086063A1

  公开（公告）日：2001-03-28
• EP1086063A4
  申请人：——

  公开号：EP1086063A4

  公开（公告）日：2001-03-28
• [EN] NOVEL THERAPEUTIC AGENTS FOR MEMBRANE TRANSPORTERS<br/>[FR] AGENTS THERAPEUTIQUES AGISSANT SUR LES TRANSPORTEURS MEMBRANAIRES
  申请人：——

  公开号：WO1999064045A9

  公开（公告）日：2001-07-05

  [EN] Disclosed are multibinding compounds that bind cell membrane transporters and modulate their activity. The multibinding compounds contain from 2 to 10 ligands covalently attached to one or more linkers.
  [FR] Cette invention concerne des composés à liaisons multiples et en module l'activité. Ces composés comportent de 2 à 10 ligands liés à un ou plusieurs lieurs.
• [EN] NOVEL POTASSIUM CHANNEL DRUGS AND THEIR USES<br/>[FR] MEDICAMENTS A CANAL POTASSIUM ET LEUR UTILISATION
  申请人：ADVANCED MEDICINE INC

  公开号：WO1999064050A1

  公开（公告）日：1999-12-16

  This invention relates to novel multibinding compounds that bind to potassium (K+) channels and modulate their activity. The compounds of this invention comprise 2-10 K+ channel ligands covalently connected by a linker or linkers, wherein the ligands in their monovalent (i.e., unlinked) state bind to one or more types of K+ channel. The manner of linking the ligands together is such that the multibinding agents thus formed demonstrate an increased biologic and/or therapeutic effect as compared to the same number of unlinked ligands made available for binding to the K+ channel. The invention also relates to methods of using such compounds and to methods of preparing them. The compounds of this invention are particularly useful for treating diseases and conditions of mammals that are mediated by K+ channels. Accordingly, this invention also relates to pharmaceutical compositions comprising a pharmaceutically acceptable excipient and an effective amount of a compound of this invention.